China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector.
Patent Details
The patent in question, titled “An E-configured benzamide compound and its pharmaceutical formulation and application” (Patent No.: ZL201410136761.X), was authorized by CNIPA in May 2017 and is valid through April 4, 2034. This patent covers the innovative compound and formulation of chidamide, a first-in-class subtype-selective histone deacetylase inhibitor.
Chidamide’s Market Approvals
Chipscreen’s chidamide has achieved three indication approvals in China for the treatment of peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma. The drug is also registered in Taiwan for the treatment of breast cancer and in Japan for use in leukemia and peripheral T-cell lymphoma. These approvals highlight the drug’s therapeutic potential and market reach in the Asia-Pacific region.
Strategic Implications
The acceptance of the patent invalidation request for review by CNIPA underscores the importance of robust intellectual property protection in the pharmaceutical industry. For Chipscreen, this review process is crucial in maintaining the exclusivity and commercial viability of chidamide. The outcome of this review could have significant implications for the company’s market position and future development plans.-Fineline Info & Tech
Leave a Reply